Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
53.16 USD | -4.48% | -4.34% | -14.19% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.19% | 4.72B | |
+1.23% | 43.84B | |
+6.60% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+7.54% | 25.53B | |
-24.79% | 18.18B | |
-3.59% | 12.29B | |
+27.76% | 12.29B | |
+7.36% | 11.15B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : Barclays Adjusts CRISPR Therapeutics PT to $140 From $113, Maintains Overweight Rating